Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: Randomised controlled trialCitation formats

  • External authors:
  • Christine Barrowclough
  • Til Wykes
  • Ruth Beardmore
  • Patricia Conrod
  • Tom Craig
  • Graham Dunn
  • Jan Moring
  • Craig Steel
  • Nicholas Tarrier

Standard

Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: Randomised controlled trial. / Barrowclough, Christine; Haddock, Gillian; Wykes, Til; Beardmore, Ruth; Conrod, Patricia; Craig, Tom; Davies, Linda; Dunn, Graham; Eisner, Emily; Lewis, Shôn; Moring, Jan; Steel, Craig; Tarrier, Nicholas.

In: B M J , Vol. 341, No. 7784, c6325, 04.12.2010, p. 1204.

Research output: Contribution to journalArticlepeer-review

Harvard

Barrowclough, C, Haddock, G, Wykes, T, Beardmore, R, Conrod, P, Craig, T, Davies, L, Dunn, G, Eisner, E, Lewis, S, Moring, J, Steel, C & Tarrier, N 2010, 'Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: Randomised controlled trial', B M J , vol. 341, no. 7784, c6325, pp. 1204. https://doi.org/10.1136/bmj.c6325

APA

Barrowclough, C., Haddock, G., Wykes, T., Beardmore, R., Conrod, P., Craig, T., Davies, L., Dunn, G., Eisner, E., Lewis, S., Moring, J., Steel, C., & Tarrier, N. (2010). Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: Randomised controlled trial. B M J , 341(7784), 1204. [c6325]. https://doi.org/10.1136/bmj.c6325

Vancouver

Author

Barrowclough, Christine ; Haddock, Gillian ; Wykes, Til ; Beardmore, Ruth ; Conrod, Patricia ; Craig, Tom ; Davies, Linda ; Dunn, Graham ; Eisner, Emily ; Lewis, Shôn ; Moring, Jan ; Steel, Craig ; Tarrier, Nicholas. / Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: Randomised controlled trial. In: B M J . 2010 ; Vol. 341, No. 7784. pp. 1204.

Bibtex

@article{2af16eec575349ffa33d1b3b10e320a0,
title = "Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: Randomised controlled trial",
abstract = "OBJECTIVES: To evaluate the effectiveness of integrated motivational interviewing and cognitive behavioural therapy in addition to standard care for patients with psychosis and a comorbid substance use problem. DESIGN: Two centre, open, rater blind randomised controlled trial. SETTING: Secondary care in the United Kingdom. PARTICIPANTS: 327 patients with a clinical diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder and a diagnosis of dependence on or misuse of drugs, alcohol, or both according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition. INTERVENTION: The intervention was integrated motivational interviewing and cognitive behavioural therapy plus standard care, which was compared with standard care alone. Phase one of therapy-{"}motivation building{"}-concerns engaging the patient, then exploring and resolving ambivalence for change in substance use. Phase two-{"}action{"}-supports and facilitates change using cognitive behavioural approaches. Up to 26 therapy sessions were delivered over one year. MAIN OUTCOME MEASURES: The primary outcome was death from any cause or admission to hospital in the 12 months after completion of therapy. Secondary outcomes were frequency and amount of substance use (assessed using the timeline followback method), readiness to change, perceived negative consequences of use, psychotic symptom ratings, number and duration of relapses, and global assessment of functioning and deliberate self harm at 12 and 24 months, with additional timeline followback assessments at 6 and 18 months. Analysis was by intention to treat and robust treatment effect estimates were produced. RESULTS: 327 participants were randomly allocated to either the intervention (n=164) or treatment as usual (n=163). At 24 months, 326 (99.7%) were assessed on the primary outcome and 246 (75.2%) on the main secondary outcomes. Treatment had no beneficial effect on hospital admissions or death during follow-up, with 23.3% (38/163) of the therapy group and 20.2% (33/163) of controls deceased or admitted (adjusted odds ratio 1.16, 95% confidence interval 0.68 to 1.99; P=0.579). Therapy had no effect on the frequency of substance use or the perceived negative consequences of misuse, but did have a statistically significant effect on amount used per substance using day (adjusted ORs for main substance 1.50, 95% CI 1.08 to 2.09; P=0.016; and all substances 1.48, 95% CI 1.07 to 2.05; P=0.017). Treatment had a statistically significant effect on readiness to change use at 12 months (adjusted OR 2.05, 95% CI 1.26 to 3.31; P=0.004) that was not maintained at 24 months (0.78, 95% CI 0.48 to 1.28; P=0.320). There were no effects of treatment on clinical outcomes such as relapses, psychotic symptoms, functioning, and self harm. CONCLUSIONS: Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and substance misuse do not improve outcome in terms of hospitalisation, symptom outcomes, or functioning. This approach does reduce the amount of substance used for at least one year after completion of therapy. TRIAL REGISTRATION: Current Controlled Trials: ISRCTN14404480.",
author = "Christine Barrowclough and Gillian Haddock and Til Wykes and Ruth Beardmore and Patricia Conrod and Tom Craig and Linda Davies and Graham Dunn and Emily Eisner and Sh{\^o}n Lewis and Jan Moring and Craig Steel and Nicholas Tarrier",
note = "G0200471, Medical Research Council, United KingdomGO200471, Medical Research Council, United Kingdom, Department of Health, United Kingdom",
year = "2010",
month = dec,
day = "4",
doi = "10.1136/bmj.c6325",
language = "English",
volume = "341",
pages = "1204",
journal = "British Medical Journal",
issn = "0959-535X",
publisher = "BMJ ",
number = "7784",

}

RIS

TY - JOUR

T1 - Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: Randomised controlled trial

AU - Barrowclough, Christine

AU - Haddock, Gillian

AU - Wykes, Til

AU - Beardmore, Ruth

AU - Conrod, Patricia

AU - Craig, Tom

AU - Davies, Linda

AU - Dunn, Graham

AU - Eisner, Emily

AU - Lewis, Shôn

AU - Moring, Jan

AU - Steel, Craig

AU - Tarrier, Nicholas

N1 - G0200471, Medical Research Council, United KingdomGO200471, Medical Research Council, United Kingdom, Department of Health, United Kingdom

PY - 2010/12/4

Y1 - 2010/12/4

N2 - OBJECTIVES: To evaluate the effectiveness of integrated motivational interviewing and cognitive behavioural therapy in addition to standard care for patients with psychosis and a comorbid substance use problem. DESIGN: Two centre, open, rater blind randomised controlled trial. SETTING: Secondary care in the United Kingdom. PARTICIPANTS: 327 patients with a clinical diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder and a diagnosis of dependence on or misuse of drugs, alcohol, or both according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition. INTERVENTION: The intervention was integrated motivational interviewing and cognitive behavioural therapy plus standard care, which was compared with standard care alone. Phase one of therapy-"motivation building"-concerns engaging the patient, then exploring and resolving ambivalence for change in substance use. Phase two-"action"-supports and facilitates change using cognitive behavioural approaches. Up to 26 therapy sessions were delivered over one year. MAIN OUTCOME MEASURES: The primary outcome was death from any cause or admission to hospital in the 12 months after completion of therapy. Secondary outcomes were frequency and amount of substance use (assessed using the timeline followback method), readiness to change, perceived negative consequences of use, psychotic symptom ratings, number and duration of relapses, and global assessment of functioning and deliberate self harm at 12 and 24 months, with additional timeline followback assessments at 6 and 18 months. Analysis was by intention to treat and robust treatment effect estimates were produced. RESULTS: 327 participants were randomly allocated to either the intervention (n=164) or treatment as usual (n=163). At 24 months, 326 (99.7%) were assessed on the primary outcome and 246 (75.2%) on the main secondary outcomes. Treatment had no beneficial effect on hospital admissions or death during follow-up, with 23.3% (38/163) of the therapy group and 20.2% (33/163) of controls deceased or admitted (adjusted odds ratio 1.16, 95% confidence interval 0.68 to 1.99; P=0.579). Therapy had no effect on the frequency of substance use or the perceived negative consequences of misuse, but did have a statistically significant effect on amount used per substance using day (adjusted ORs for main substance 1.50, 95% CI 1.08 to 2.09; P=0.016; and all substances 1.48, 95% CI 1.07 to 2.05; P=0.017). Treatment had a statistically significant effect on readiness to change use at 12 months (adjusted OR 2.05, 95% CI 1.26 to 3.31; P=0.004) that was not maintained at 24 months (0.78, 95% CI 0.48 to 1.28; P=0.320). There were no effects of treatment on clinical outcomes such as relapses, psychotic symptoms, functioning, and self harm. CONCLUSIONS: Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and substance misuse do not improve outcome in terms of hospitalisation, symptom outcomes, or functioning. This approach does reduce the amount of substance used for at least one year after completion of therapy. TRIAL REGISTRATION: Current Controlled Trials: ISRCTN14404480.

AB - OBJECTIVES: To evaluate the effectiveness of integrated motivational interviewing and cognitive behavioural therapy in addition to standard care for patients with psychosis and a comorbid substance use problem. DESIGN: Two centre, open, rater blind randomised controlled trial. SETTING: Secondary care in the United Kingdom. PARTICIPANTS: 327 patients with a clinical diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder and a diagnosis of dependence on or misuse of drugs, alcohol, or both according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition. INTERVENTION: The intervention was integrated motivational interviewing and cognitive behavioural therapy plus standard care, which was compared with standard care alone. Phase one of therapy-"motivation building"-concerns engaging the patient, then exploring and resolving ambivalence for change in substance use. Phase two-"action"-supports and facilitates change using cognitive behavioural approaches. Up to 26 therapy sessions were delivered over one year. MAIN OUTCOME MEASURES: The primary outcome was death from any cause or admission to hospital in the 12 months after completion of therapy. Secondary outcomes were frequency and amount of substance use (assessed using the timeline followback method), readiness to change, perceived negative consequences of use, psychotic symptom ratings, number and duration of relapses, and global assessment of functioning and deliberate self harm at 12 and 24 months, with additional timeline followback assessments at 6 and 18 months. Analysis was by intention to treat and robust treatment effect estimates were produced. RESULTS: 327 participants were randomly allocated to either the intervention (n=164) or treatment as usual (n=163). At 24 months, 326 (99.7%) were assessed on the primary outcome and 246 (75.2%) on the main secondary outcomes. Treatment had no beneficial effect on hospital admissions or death during follow-up, with 23.3% (38/163) of the therapy group and 20.2% (33/163) of controls deceased or admitted (adjusted odds ratio 1.16, 95% confidence interval 0.68 to 1.99; P=0.579). Therapy had no effect on the frequency of substance use or the perceived negative consequences of misuse, but did have a statistically significant effect on amount used per substance using day (adjusted ORs for main substance 1.50, 95% CI 1.08 to 2.09; P=0.016; and all substances 1.48, 95% CI 1.07 to 2.05; P=0.017). Treatment had a statistically significant effect on readiness to change use at 12 months (adjusted OR 2.05, 95% CI 1.26 to 3.31; P=0.004) that was not maintained at 24 months (0.78, 95% CI 0.48 to 1.28; P=0.320). There were no effects of treatment on clinical outcomes such as relapses, psychotic symptoms, functioning, and self harm. CONCLUSIONS: Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and substance misuse do not improve outcome in terms of hospitalisation, symptom outcomes, or functioning. This approach does reduce the amount of substance used for at least one year after completion of therapy. TRIAL REGISTRATION: Current Controlled Trials: ISRCTN14404480.

U2 - 10.1136/bmj.c6325

DO - 10.1136/bmj.c6325

M3 - Article

C2 - 21106618

VL - 341

SP - 1204

JO - British Medical Journal

JF - British Medical Journal

SN - 0959-535X

IS - 7784

M1 - c6325

ER -